Skip to main content

Table 1 Patients characteristics

From: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience

Variable Whole cohort N (%) RAI ablation N (%) Without RAI ablation N (%) P value*
 Total patients 326/1192 (27.4 %) 182/326 (55.8) 144/326 (44.2) 0.06
Age (years) 42.6 (18–76) SD ±11.6 43.2 (18–76) SD ± 12.4 41.8 (19–71) SD ± 10.2  
  ≤45 years 201 (61.7) 110 (60.4) 94 (65.3) 0.81
  ≥45 years 125 (38.3) 72 (39.6) 50 (34.7)  
Gender
  Female 271 (83.1) 146 (80.2) 125 (86.8) 0.06
  Male 55 (16.9) 36 (19.8) 19 (13.2)  
 Female to male ratio 4.9 4.0 6.5  
Type of surgery
 Total thyroidectomy 299 (91.7) 182 (100) 117 (81.3) 0.04
 Hemi-thyroidectomy 27 (8.3) - 27 (18.7)  
Lymph node surgery
 Central neck dissection 88 (27.0) 54 (29.7) 34 (23.6)  
 Lateral neck dissection 18 (5.5) 9 (4.9) 9 (6.3) 0.9
 Sampling 55 (16.9) 25 (13.7) 30 (20.8)  
 None 165 (50.6) 94 (51.7) 71 (49.3)  
Mean size (cm) 0.61 (0.1–1.0) ± 0.24 0.72 (0.2–1.0) ± 0.21 0.44 (0.1–0.9) ± 0.2  
  ≤0.5 cm 161 (49.4) 50 (27.5) 111 (77.1) <0.0001
  ≥0.5 cm 165 (50.6) 132 (72.5) 33 (22.9)  
Histopathologic variants
  Classic 265 (81.3) 143 (78.6) 122 (84.7)  
  Follicular 41 (12.6) 21 (11.5) 20 (13.9)  
  Hurthle cell 8 (2.5) 6 (3.3) 2 (1.4)  
  Tall cell 11 (3.4) 11 (6.0) - 0.001
  Sclerosing 1 (0.3) 1 (0.5) -  
Multifocal
  Yes 125 (38.3) 122 (67.1) 3 (2.1) <0.0001
  No 201 (61.7) 60 (32.9) 141 (97.9)  
ETE
  Yes 62 (19.0) 57 (31.3) 5 (3.5) <0.0001
  No 264 (81.0) 125 (68.7) 139 (96.5)  
LVSI
  Yes 55 (16.9) 49 (26.9) 6 (4.2) <0.0001
  No 271 (83.1) 133 (73.1) 138 (95.8)  
Surgical margins
  Positive 35 (10.7) 30 (16.5) 5 (3.5) <0.0001
  Negative 291 (89.3) 152 (83.5) 139 (96.5)  
Lymph node metastasis
  Yes 42 (12.9) 42 (23.1) - <0.0001
  N1a 34 (73.8) 34 (73.8)   
  N1b 8 (19.2) 8 (19.2)   
  No 284 (87.1) 140 (76.9) 144 (100)  
Background thyroid tissue
 Normal 98 (30.1) 47 (25.8) 51 (35.4)  
 Multi-nodular goiter 106 (32.5) 60 (32.9) 46 (31.9)  
 Lymphocytic thyroiditis/Hashimotos’ thyroiditis 122 (37.5) 75 (41.3) 47 (32.6) 0.052
Distant Metastasis at presentation 3 (0.9) 3 (1.65) - <0.0001
AJCC staging
  I 217 (66.5) 73 (40.1) 139 (96.5)  
  II - - -  
  III 96 (29.5) 96 (52.6) 5 (3.5) <0.0001
  IVA 10 (3.1) 10 (5.6) -  
  IVB - - -  
  IVC 3 (0.9) 3 (1.7) -  
Mean postoperative TG (ng/ml) 1.39 (0.1–42890) 2.44 (0.1–42890) 0.39 (0.1–8.9) 0.62
RAI dose
  30 mCi   50 (27.5) - <0.0001
  100 mCi   85 (46.7) -  
  150-200 mCi   47 (25.8) -  
RT to Neck 2 (0.61) 2 (1.1) - <0.0001
Recurrences     
 Locoregional 13 (3.9) 4 (2.2) 9 (6.2) <0.001
 Distant 10 (3.1) 4 (2.2) 6 (4.2)  
  1. *P value pertaining to the variation in clinicopathological characteristics between two groups
  2. RAI radioactive iodine 131, N number, SD standard deviation, ETE extra-thyroidal extension, LVSI lymphovascular space invasion, AJCC American joint committee on cancer, TG thyroglobulin, mCi millicurie, RT radiation therapy